Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $46.22

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $46.22.

Several research analysts have recently issued reports on the stock. Piper Sandler assumed coverage on shares of AnaptysBio in a research note on Friday, February 16th. They issued an "overweight" rating and a $80.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They issued a "buy" rating and a $50.00 target price on the stock. Leerink Partnrs reiterated an "outperform" rating on shares of AnaptysBio in a research note on Tuesday, April 16th. BTIG Research assumed coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a "buy" rating and a $55.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Monday, April 1st.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company's stock, valued at $81,000. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company's stock, valued at $81,000. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Daniel Faga sold 145,940 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now directly owns 752,087 shares of the company's stock, valued at $17,132,541.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 153,940 shares of company stock valued at $3,513,773. Insiders own 35.50% of the company's stock.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of ANAB. Allspring Global Investments Holdings LLC purchased a new stake in shares of AnaptysBio in the first quarter worth $38,000. China Universal Asset Management Co. Ltd. increased its stake in shares of AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 2,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 3,381 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of AnaptysBio in the fourth quarter worth $119,000. Finally, SG Americas Securities LLC purchased a new stake in shares of AnaptysBio in the fourth quarter worth $126,000.

AnaptysBio Price Performance

NASDAQ:ANAB traded up $1.68 during mid-day trading on Wednesday, hitting $26.02. 794,807 shares of the company's stock were exchanged, compared to its average volume of 337,769. AnaptysBio has a one year low of $13.36 and a one year high of $27.50. The business has a fifty day moving average price of $22.89 and a 200 day moving average price of $20.68. The company has a market cap of $710.87 million, a PE ratio of -4.28 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. On average, equities analysts forecast that AnaptysBio will post -6.17 EPS for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.